Latest Breaking News On - John nicols - Page 5 : comparemela.com

FDA Separately Grants Lantern Pharma and Codexis Rare Pediatric Disease Designations

Codexis Launches Codex® HiTemp Reverse Transcriptase to Address Key Challenges in One-Step Assays for RNA Detection in PCR Testing, including COVID-19 Testing

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its Codex® HiTemp Reverse Transcriptase for use in one-step quantitative reverse transcription PCR (RT-qPCR).

Codexis product revenue up 227% over last year : Biofuels Digest

Codexis and Kalsec Announce Expanded Collaboration for Supply of Novel Enzyme to Sustainably Produce Natural Clean-Label Beverage Ingredient

Home / Top News / Codexis and Kalsec Announce Expanded Collaboration for Supply of Novel Enzyme to Sustainably Produce Natural Clean-Label Beverage Ingredient Codexis and Kalsec Announce Expanded Collaboration for Supply of Novel Enzyme to Sustainably Produce Natural Clean-Label Beverage Ingredient REDWOOD CITY, Calif. and KALAMAZOO, Mich., July 26, 2021 (GLOBE NEWSWIRE) Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Kalsec, Inc., a leading global producer of natural spice and herb extracts, colors, food protection and hop extracts for the food and beverage industry, announced that the companies have expanded their research collaboration and entered into an exclusive supply agreement for a novel enzyme to produce Kalsec’s newest natural hop acid.

Molecular Assemblies Closes Oversubscribed $24 Million Series A Financing to Advance Enzymatic DNA Synthesis toward Initial Commercial Access

Molecular Assemblies Closes Oversubscribed $24 Million Series A Financing to Advance Enzymatic DNA Synthesis toward Initial Commercial Access News provided by Share this article Share this article SAN DIEGO, April 15, 2021 /PRNewswire/  Molecular Assemblies, Inc., today announced that it has closed an oversubscribed $24 million Series A financing with significant investment from Agilent Technologies, iSelect Fund, Codexis, Alexandria Venture Investments, and Argonautic Ventures. In addition LYFE Capital has joined the syndicate. The proceeds of the financing will be used to advance the company s proprietary enzymatic DNA synthesis technology toward early commercialization efforts. We have made significant progress in advancing our proprietary enzymatic DNA synthesis technology, said Michael J. Kamdar, President and CEO of Molecular Assemblies. Over the past year, we ve entered into a transformative partnership with Codexis and joined a new project with GE Research to enabl